Agios Pharmaceuticals, Inc., a company working in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, will receive $1.1 billion in milestone payments following the U.S. FDA approval of vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery, including biopsy, sub-total resection or gross total resection.    The payments include $905 million from Royalty Pharma in connection with the voraside...